trial

Bioequivalence Study in Patients With Schizophrenia by Using Clozaril 100 mg Tablet (Clozapine) and WID-CLZ18

NCTId NCT04849026
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 33 (actual)
Sponsored by Whanin Pharmaceutical Company
Primary completion 2022-08-14
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
33 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
None
Start
2021-01-15
Primary completion
2022-08-14
Eligibility
ALL · 20 Years · 65 Years

Interventions & indications

Drugs
ClozapineWID-CLZ18

Sponsors

Whanin Pharmaceutical CompanyLead Sponsor

Investigators

1
Bo-Hyun YoonPrincipal Investigator

Sites

1 total
Seoul, South Korea

Facts & assertions

4 sourced
Enrollment
33
Phase
PHASE1
Primary Completion Date
2022-08-14
Status
COMPLETED
relationships
The graph out of here
drug
Clozapine
drug
WID-CLZ18
drug
lead_sponsor
Whanin Pharmaceutical Company
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Bo-Hyun Yoon
person